214 related articles for article (PubMed ID: 12957861)
21. Thrombospondins 1 and 2 function as inhibitors of angiogenesis.
Armstrong LC; Bornstein P
Matrix Biol; 2003 Mar; 22(1):63-71. PubMed ID: 12714043
[TBL] [Abstract][Full Text] [Related]
22. Identification of TAX2 peptide as a new unpredicted anti-cancer agent.
Jeanne A; Sick E; Devy J; Floquet N; Belloy N; Theret L; Boulagnon-Rombi C; Diebold MD; Dauchez M; Martiny L; Schneider C; Dedieu S
Oncotarget; 2015 Jul; 6(20):17981-8000. PubMed ID: 26046793
[TBL] [Abstract][Full Text] [Related]
23. Chronic delivery of a thrombospondin-1 mimetic decreases skeletal muscle capillarity in mice.
Audet GN; Fulks D; Stricker JC; Olfert IM
PLoS One; 2013; 8(2):e55953. PubMed ID: 23405239
[TBL] [Abstract][Full Text] [Related]
24. The cell biology of thrombospondin-1.
Chen H; Herndon ME; Lawler J
Matrix Biol; 2000 Dec; 19(7):597-614. PubMed ID: 11102749
[TBL] [Abstract][Full Text] [Related]
25. Lysophosphatidic acid suppresses endothelial cell CD36 expression and promotes angiogenesis via a PKD-1-dependent signaling pathway.
Ren B; Hale J; Srikanthan S; Silverstein RL
Blood; 2011 Jun; 117(22):6036-45. PubMed ID: 21441463
[TBL] [Abstract][Full Text] [Related]
26. Ligand-induced growth and compaction of CD36 nanoclusters enriched in Fyn induces Fyn signaling.
Githaka JM; Vega AR; Baird MA; Davidson MW; Jaqaman K; Touret N
J Cell Sci; 2016 Nov; 129(22):4175-4189. PubMed ID: 27694211
[TBL] [Abstract][Full Text] [Related]
27. CD36 ectodomain phosphorylation blocks thrombospondin-1 binding: structure-function relationships and regulation by protein kinase C.
Chu LY; Silverstein RL
Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):760-7. PubMed ID: 22247259
[TBL] [Abstract][Full Text] [Related]
28. Expression, purification and structural characterization of functionally replete thrombospondin-1 type 1 repeats in a bacterial expression system.
Klenotic PA; Page RC; Misra S; Silverstein RL
Protein Expr Purif; 2011 Dec; 80(2):253-9. PubMed ID: 21821127
[TBL] [Abstract][Full Text] [Related]
29. Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes.
Cursiefen C; Maruyama K; Bock F; Saban D; Sadrai Z; Lawler J; Dana R; Masli S
J Exp Med; 2011 May; 208(5):1083-92. PubMed ID: 21536744
[TBL] [Abstract][Full Text] [Related]
30. Plasmodium falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for adherence to CD36, thrombospondin, and intercellular adhesion molecule 1.
Baruch DI; Gormely JA; Ma C; Howard RJ; Pasloske BL
Proc Natl Acad Sci U S A; 1996 Apr; 93(8):3497-502. PubMed ID: 8622965
[TBL] [Abstract][Full Text] [Related]
31. Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level.
Zhang X; Kazerounian S; Duquette M; Perruzzi C; Nagy JA; Dvorak HF; Parangi S; Lawler J
FASEB J; 2009 Oct; 23(10):3368-76. PubMed ID: 19528255
[TBL] [Abstract][Full Text] [Related]
32. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1.
Isenberg JS; Ridnour LA; Dimitry J; Frazier WA; Wink DA; Roberts DD
J Biol Chem; 2006 Sep; 281(36):26069-80. PubMed ID: 16835222
[TBL] [Abstract][Full Text] [Related]
33. CD36 as a multiple-ligand signaling receptor in atherothrombosis.
Nergiz-Unal R; Rademakers T; Cosemans JM; Heemskerk JW
Cardiovasc Hematol Agents Med Chem; 2011 Jan; 9(1):42-55. PubMed ID: 20939828
[TBL] [Abstract][Full Text] [Related]
34. Thrombospondin-1/CD36 pathway contributes to bone marrow-derived angiogenic cell dysfunction in type 1 diabetes via Sonic hedgehog pathway suppression.
Wang JM; Isenberg JS; Billiar TR; Chen AF
Am J Physiol Endocrinol Metab; 2013 Dec; 305(12):E1464-72. PubMed ID: 24148348
[TBL] [Abstract][Full Text] [Related]
35. CD36 and Its Role in Regulating the Tumor Microenvironment.
Liao X; Yan S; Li J; Jiang C; Huang S; Liu S; Zou X; Zhang G; Zou J; Liu Q
Curr Oncol; 2022 Oct; 29(11):8133-8145. PubMed ID: 36354702
[TBL] [Abstract][Full Text] [Related]
36. Novel antiangiogenic pathway of thrombospondin-1 mediated by suppression of the cell cycle.
Yamauchi M; Imajoh-Ohmi S; Shibuya M
Cancer Sci; 2007 Sep; 98(9):1491-7. PubMed ID: 17596205
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma.
Tanaka K; Sonoo H; Kurebayashi J; Nomura T; Ohkubo S; Yamamoto Y; Yamamoto S
Clin Cancer Res; 2002 May; 8(5):1125-31. PubMed ID: 12006528
[TBL] [Abstract][Full Text] [Related]
38. LPA/PKD-1-FoxO1 Signaling Axis Mediates Endothelial Cell CD36 Transcriptional Repression and Proangiogenic and Proarteriogenic Reprogramming.
Ren B; Best B; Ramakrishnan DP; Walcott BP; Storz P; Silverstein RL
Arterioscler Thromb Vasc Biol; 2016 Jun; 36(6):1197-208. PubMed ID: 27013613
[TBL] [Abstract][Full Text] [Related]
39. Lysosomal integral membrane protein II binds thrombospondin-1. Structure-function homology with the cell adhesion molecule CD36 defines a conserved recognition motif.
Crombie R; Silverstein R
J Biol Chem; 1998 Feb; 273(9):4855-63. PubMed ID: 9478926
[TBL] [Abstract][Full Text] [Related]
40. Identification of CD36 molecular features required for its in vitro angiostatic activity.
Primo L; Ferrandi C; Roca C; Marchiò S; di Blasio L; Alessio M; Bussolino F
FASEB J; 2005 Oct; 19(12):1713-5. PubMed ID: 16037098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
